|
22 Apr 2021 |
Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
|
|
14 Apr 2021 |
Aquavit to Introduce A New Botulinum Toxin (DTX-021)
|
|
13 Apr 2021 |
Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy
|
|
13 Apr 2021 |
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
|
|
12 Apr 2021 |
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
|
|
12 Apr 2021 |
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
|
|
12 Apr 2021 |
Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
|
|
11 Apr 2021 |
Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities
|
|
06 Apr 2021 |
Molecular Templates to Prioritize Next-Generation ETB Candidates
|
|
06 Apr 2021 |
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
|
|
06 Apr 2021 |
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
|
|
02 Apr 2021 |
Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta™
|
|
30 Mar 2021 |
D&D Pharmatech Announces First Patient Dosed in Phase 1 Clinical Trial of DD01 in Obese Patients with Diabetes and NAFLD
|
|
27 Mar 2021 |
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12–17 years
|
|
24 Mar 2021 |
Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform
|
|
23 Mar 2021 |
JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan
|
|
23 Mar 2021 |
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
|
|
23 Mar 2021 |
Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
|
|
23 Mar 2021 |
Zealand Pharma Announces FDA Approval of Zegalogue (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes
|
|
22 Mar 2021 |
Cybrexa Therapeutics Receives Green Light from FDA on Investigational New Drug Application for CBX-12 (alphalex™-exatecan)
|
|
22 Mar 2021 |
Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)
|
|
20 Mar 2021 |
Amyndas Announces Positive Top-Line Phase 2 Results for Investigational AMY-101 in Adults With Periodontal Inflammation and Gingivitis
|
|
16 Mar 2021 |
CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
|
|
15 Mar 2021 |
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
|
|
09 Mar 2021 |
Affibody and Inmagene announce IND Clearance for izokibep (ABY-035) for the treatment of Non-infectious Non-anterior Uveitis
|
